H5N1 vaccine

Sanofi to build new manufacturing facility in Toronto to strengthen domestic pandemic preparedness and increase global supply of high-dose influenza vaccine

Retrieved on: 
Wednesday, March 31, 2021
Health, Articles, Medical specialties, Influenza vaccine, Vaccines, Vaccination, Sanofi, Vaccine, Influenza, Pandemic, Seasonal influenza vaccine brands, H5N1 vaccine

In addition, it will be a key resource to assist against future pandemics," said Paul Hudson, Chief Executive Officer, Sanofi.

Key Points: 
  • In addition, it will be a key resource to assist against future pandemics," said Paul Hudson, Chief Executive Officer, Sanofi.
  • In addition to producing Sanofi's FLUZONE High-Dose Quadrivalent influenza vaccine, this new manufacturing facility will strategically grow Canada's bio-manufacturing sector and install industrial scale capacity to strengthen Canada's preparedness for future pandemics.
  • "With the help of our government partners, bringing this new facility on Canadian soil will increase domestic vaccine manufacturing capacity, strengthen future national pandemic preparedness efforts and bolster worldwide supply of our differentiated influenza vaccines."
  • Following design, construction, testing, and qualification of the facility and equipment, the new Toronto Site facility will be operational by 2026.

European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older

Retrieved on: 
Wednesday, November 18, 2020
Vaccination, Medical specialties, Drugs, Vaccines, Influenza vaccines, Influenza vaccine, Influenza, Vaccine, Live attenuated influenza vaccine, Seasonal influenza vaccine brands, H5N1 vaccine, Vaccination, Medical specialties, Drugs, Vaccines, Influenza vaccines, Influenza vaccine, Influenza, Vaccine, Live attenuated influenza vaccine, Seasonal influenza vaccine brands, H5N1 vaccine

Phase 3 efficacy trial demonstrated improved protection against influenza compared to standard-dose influenza vaccine, and reduced the risk of influenza by an additional 30% in adults aged 50 years and older1,2

Key Points: 
  • Phase 3 efficacy trial demonstrated improved protection against influenza compared to standard-dose influenza vaccine, and reduced the risk of influenza by an additional 30% in adults aged 50 years and older1,2
    PARIS November 18, 2020 The European Commission has granted a marketing authorization for Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older.
  • Supemtek is the first and only recombinant influenza vaccine now approved in the European Union.
  • This increased amount of antigen and the use of recombinant technology provide improved protection against influenza, particularly in those aged 50 and older.
  • In comparison with a standard-dose egg-based quadrivalent influenza vaccine, Supemtek reduced the risk of influenza by an additional 30% for adults aged 50 years and older1,2.

Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine

Retrieved on: 
Friday, July 31, 2020
Vaccines, Health, Drugs, Medical research, RTT, CAC 40, Sanofi, COVID-19 vaccine, Influenza vaccine, Vaccine, H5N1 clinical trials, H5N1 vaccine

PARIS and LONDON July 31, 2020 Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine.

Key Points: 
  • PARIS and LONDON July 31, 2020 Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine.
  • The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSKs established adjuvant technology.
  • Together with GSK, we are working relentlessly to develop and produce a vaccine to address this global health crisis.
  • Translate Bio has established mRNA manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine

Retrieved on: 
Wednesday, July 29, 2020
Health, Vaccination, Vaccines, Sanofi, Adjuvants, RTT, CAC 40, Vaccine, Influenza vaccine, H5N1 clinical trials, H5N1 vaccine

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSKs established pandemic adjuvant technology.

Key Points: 
  • The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSKs established pandemic adjuvant technology.
  • We greatly appreciate the UK governments support of this shared vision, said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur.
  • In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year overall.
  • Translate Bio has established mRNA manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

Retrieved on: 
Monday, July 20, 2020
Vaccination, Vaccine, Virology, Medical specialties, Medicine, RTT, Vaccines, Influenza research, Health, H5N1 vaccine

Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.

Key Points: 
  • Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.
  • This agreement is a testament to our shared goal to have millions of doses of a vaccine against COVID-19 available before the end of the year.
  • We are in advanced discussions with multiple other government bodies and hope to announce additional supply agreements soon.
  • Finding a vaccine is one way that we will end the pandemic and return to normal life.

ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production

Retrieved on: 
Wednesday, July 15, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious diseases, Medical specialties, Vaccination, Medicine, Branches of biology, Virology, Immune system, Vaccines, Vaccine, Antigen, Edible vaccines, H5N1 vaccine, ZYUS Life Sciences Inc., VIDO-InterVac, University of Saskatchewan

Over the past months, ZYUS researchers have been working to determine whether plants can offer an alternative method of antigen production to traditional production methods for vaccines.

Key Points: 
  • Over the past months, ZYUS researchers have been working to determine whether plants can offer an alternative method of antigen production to traditional production methods for vaccines.
  • Plant-based antigen production, leveraging ZYUS proprietary bio-technology platform, offers the potential to produce large quantities of vaccine-quality antigens rapidly and efficiently.
  • Meaningful recovery of the protein from plants, establishing that ZYUS plant expression technology offers an efficient means of protein production relative to the starting amount of plant material.
  • Rapid production of large quantities of an antigen with suitable purity and quality is a critical step in developing a vaccine for COVID-19, said Brent Zettl, ZYUS CEO.

COVID-19 Vaccine Candidates and Developing World WHO Vaccine Candidates - 2020 Pipeline Tracker

Retrieved on: 
Thursday, May 21, 2020
Vaccines, Drugs, Medicine, Vaccination, Vaccine, Virology, RTT, Hypothetical technology, Influenza vaccine, H5N1 vaccine

DUBLIN, May 21, 2020 /PRNewswire/ -- The "Vaccine Development and Production Trends, COVID-19 and Other Vaccines Pipeline" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 21, 2020 /PRNewswire/ -- The "Vaccine Development and Production Trends, COVID-19 and Other Vaccines Pipeline" report has been added to ResearchAndMarkets.com's offering.
  • The vaccine market is poised for a rather substantial increase in the next five years due to the number of vaccines in development and the push for a COVID-19 vaccine.
  • As the COVID-19 outbreak advanced worldwide, companies stepped up to the challenge, scrambling to provide a potential vaccine.
  • Vaccine Development and Production Trends, COVID-19, and Other Vaccines Pipeline outlines the issues and trends affecting the vaccine industry, including:

Generex Biotechnology Provides Update on the Development of an Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic

Retrieved on: 
Tuesday, April 14, 2020
Vaccines, Medical specialties, Medicine, Vaccination, Vaccine, Virology, HIV/AIDS in the United States, Influenza research, H5N1 vaccine

Generex is collaborating with private collaborators and academic experts to evaluate a number of peptide vaccine candidates for future clinical use.

Key Points: 
  • Generex is collaborating with private collaborators and academic experts to evaluate a number of peptide vaccine candidates for future clinical use.
  • Generex is also in discussion with U.S. and international governments to support clinical development and manufacturing capabilities for a vaccine.
  • Researchers across the world, including Generex, are investigating new products for the treatment and prevention of COVID-19, including the development of numerous vaccine modalities.
  • Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Thomas Jefferson University Researches A New Coronavirus Vaccine Designed to Meet a Global Demand

Retrieved on: 
Tuesday, April 7, 2020
Vaccines, Drugs, Vaccination, Vaccine, Virology, Medicine, RTT, Papillomavirus, Influenza research, H5N1 vaccine

"Our vaccine candidate, CORAVAX, is made from part of the current coronavirus and that is combined with another proven vaccine that serves as a carrier of sorts," says Matthias Schnell , PhD, Director of the Jefferson Vaccine Center .

Key Points: 
  • "Our vaccine candidate, CORAVAX, is made from part of the current coronavirus and that is combined with another proven vaccine that serves as a carrier of sorts," says Matthias Schnell , PhD, Director of the Jefferson Vaccine Center .
  • "The benefit is that the 'carrier' vaccine has already been rigorously tested and shown to be safe and effective.
  • There are manufacturing plants around the world already running and with the technological know-how to produce large quantities of that vaccine.
  • Jefferson is already in discussions with a large vaccine manufacturer about a potential partnership.

Biotech Companies Concentrate on Vaccine Formulation and Distribution

Retrieved on: 
Thursday, March 19, 2020
Health, Pharmaceutical industry, Clinical research, Articles, Design of experiments, Vaccines, Validation, Validity, Clinical trial, H5N1 vaccine, Influenza research

This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine."

Key Points: 
  • This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine."
  • "We have been engaging with test developers and encouraging them to come to the FDA and work with us.
  • During the four-week validation process, Todos intends to place its first purchase order based upon the market demand identified.
  • BioNTech will supply the mRNA vaccine for clinical trials from GMP manufacturing facilities in Europe along with its partner Polymun .